Computational Modeling of the Interactions between DPP IV and Hemorphins

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Type 2 diabetes is a metabolic disorder linked to impaired insulin secretion and utilization.
• Dipeptidyl peptidase IV (DPP IV) enzyme degrades incretins, making its inhibition a therapeutic strategy for diabetes.
• Hemorphins, derived from hemoglobin, exhibit DPP IV inhibitory activity, but their binding mechanisms are unclear.

Purpose of the Study:

• To elucidate the molecular binding behavior of hemorphins with DPP IV.
• To identify specific hemorphin structures and binding sites within DPP IV.
• To assess the stability of hemorphin-DPP IV interactions using computational methods.

Main Methods:

• Protein-peptide molecular docking simulations.
• Extensive molecular dynamics (MD) simulations (500 ns).
• Analysis of binding poses and stability of hemorphins in the DPP IV active site.

Main Results:

• Hemorphins lacking specific N-terminal hydrophobic residues (LVV, VV) exhibit strong binding to conserved residues in the DPP IV active site.
• These interactions remain stable throughout extended MD simulations.
• Hemorphin 7 demonstrates high binding affinity and sustained interactions by engaging with the S1 and S2 pockets of DPP IV.

Conclusions:

• Computational modeling reveals key binding interactions between hemorphins and DPP IV.
• Hemorphin structure, particularly the absence of N-terminal hydrophobic residues, is critical for potent DPP IV inhibition.
• Hemorphin 7 is a promising candidate for further investigation as a DPP IV inhibitor for type 2 diabetes treatment.